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ORIGINAL STUDY

Comparative Quality Control Study of Widely Used
Brands of Paracetamol Tablets in Iraq
Dhaﬁr Q. Masheta*, Shafq K. Al-azzawi, Aymen A. Bash
College of Pharmacy / University of Babylon, Iraq

Abstract
Based on the World Health Organization deﬁnitions, the term quality control refers to the sum of all steps and procedures undertaken by a drug manufacturer to ensure the identity, safety, efﬁcacy and purity of a particular pharmaceutical product. Quality control is an essential operation within the ﬁeld of pharmaceutical industry and it is a vital part
of current Good Manufacture Practice. It ensures that the pharmacokinetic and the pharmacodynamics properties are
predictable and reproducible for the same active pharmaceutical ingredient when manufactured by different companies.
The quality assurance of oral solid dosage form especially tablets is a priority for drug manufacturing companies. In
addition to the apparent features of tablets, tablets must meet other physical speciﬁcations and quality standards. These
include criteria for weight, weight variation, thickness, hardness, disintegration, and dissolution. In addition the content
uniformity was investigated by HPLC technique. Thus, in this project, paracetamol tablets from ﬁve different companies
which are widely used by Iraqi population were subjected to different quality control tests to indicate whether these
products are ﬁt to the standard criteria of the United States Pharmacopeia or not. The data indicated that all tested brands
succeeded to pass most tests and failed in others.
Keywords: Tablets, Paracetamol, Quality control

1. Introduction

A

cetaminophen (trade name, Paracetamol)
belongs to the non-steroidal anti-inﬂammatory drugs. Paracetamol is commonly used as analgesic for mild to moderate pain management and
antipyretic in the treatment of fever [1,2]. It is widely
used and well known by Iraqi population for
headache and fever relief. Locally, paracetamol is
available as over the counter drug (OTC) and it is
available in different dosage forms and different
strengths in local pharmacies.
Pharmacologically, it exerts its action by inhibiting
cyclooxygenase (COX) especially COX1, COX2. It
also inhibits N-methyl-D-aspartate (NMDA) receptor, substrate P, and peroxisome proliferatoractivated receptor gamma. It leads to reduce
pain perception or the transduction of neuropathic
pain [3].
Paracetamol has weak anti-inﬂammatory effects
and usually not used for such purpose [4].

Generally, paracetamol can be used to treat several
conditions such as headache, muscle ache, fever and
cold, arthritis, backache, and toothache. Paracetamol combined with opioids is also used for severe
pain such as cancer pain and pain after surgery [5,6].
The bioavailability of paracetamol following oral
administration is about 63e89% and its protein
binding is 10e25%. It is widely metabolised in the
liver, the major resulting metabolites are glucuronide and sulphate conjugates. A minor fraction (less
than 10%) of the drug is converted to a highly
reactive alkylating metabolite which is normally
inactivated in vivo with reduced glutathione and
excreted via the kidneys as highly water-soluble
cysteine and mercapturic acid conjugates. It distributes rapidly and evenly after absorption
throughout most tissues and ﬂuids and has a volume of distribution of approximately 0.9 L/kg. Ten
to twenty percent of the drug is bound to red blood
cells. Its urinary excretion is about 85e90% after
administration [7].
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The usual side effects of the drug are nausea,
vomiting, dark urine, yellowish skin, loss of appetite
and stomach pain. Paracetamol toxicity may cause
liver damage and skin reactions [8]. The commercially available dosage form of paracetamol includes
tablets, caplets, capsules, effervescent tablets, suppositories, suspensions, injections, chewable tablets,
oral drops, syrups, elixirs and extended release
tablets. In addition, the drug is formulated in combination with other active ingredients. Recommended doses of paracetamol are: For adults and
children aged 16 years and older: 500 mg-1 g every
4e6 h up to a maximum of 4 g daily. For children
aged 12e15 years: 480e750 mg every 4e6 h up to a
maximum of four doses daily. For children aged
10e11 years: 480e500 mg every 4e6 h up to a
maximum of four doses daily. For children aged 8e9
years: 360e375 mg every 4e6 h up to a maximum of
four doses daily. For children aged 6e7 years:
240e250 mg every 4e6 h up to a maximum of four
doses daily. For children aged 4e5 years: 240 mg
every 4e6 h up to a maximum of four doses daily.
For children aged 2e3 years: 180 mg every 4e6 h up
to a maximum of four doses daily. For children aged
6 months-1 year: 120 mg every 4e6 h up to a
maximum of four doses daily. For children aged 3e5
months: 60 mg every 4e6 h up to a maximum of four
doses daily [9].
Pharmaceutical characteristics of paracetamol
tablet are the following: solid dosage form (tablets
and caplets) of paracetamol is the most widely used
pharmaceutical form of the drug worldwide. The
tablets are usually uncoated, uncolored, round or
caplet shape and compressed using different punch
strengths. The purpose of the research is to focus on
the effective and efﬁcacious aspects of the tablet in
the type of pharmaceutical dosage form. The pharmaceutical components of the tablet include the
active pharmaceutical ingredient (API) and different
excipients, which ensures efﬁcient tableting, such as
disintegrants, binders, diluent, lubricants, etc. [10].
The amount, nature and type of such excipients may
dramatically affects the therapeutic effects of the
API mainly by interfering with its absorption from
the GIT following oral administration and thereby
affecting its bioavailability (rate and extent of
absorption).
Thus, the excipients of the tablet play an essential
role in the tablet formulation. In addition, other
physical characteristics of the API and the excipients
such as particle size, crystal shape and uniformity
also play a crucial role in tablets manufacturing [11].
The study tested certain features like friability,
disintegration, hardness, weight variation and contents uniformity in order to ensure that the tablet is
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within the standards of the United States Pharmacopoeia (USP). In this project paracetamol tablets
from ﬁve different brand companies, which are
widely used in the private pharmacies in Hilla city
were subjected to different quality control. The study
is quite important, not to prove that one drug brand is
better than the others, but to provide the basis to use
these methods for quality assessment of other APIs
formulated as tablets by different companies available on a commercial scale through QC testing.
1.1. Quality control testing
The term “Quality Control” refers to “the production of a perfect product by a series of measures requiring
an organized effort by the entire company to prevent or
eliminate errors at every stage in production” [12]. In
pharmaceutical industry, QC testing ensures the
safety of the drug, its efﬁcacy as well as its effectiveness. It involves speciﬁc instruments to ensure
the quality of drug testing as per set guidelines
provided by the USP [13].
Although the assuring of product quality is principally within the responsibility of quality assurance
department, it involves many other departments
and disciplined lines within a pharmaceutical company. To be effective, it must be supported by a
team effort [14].
Premium quality must be built into a drug product during both production and process design, and
it is an essential aspect of good manufacture practice
(GMP). It is inﬂuenced by many factors in addition
to the production process such as the physical plant
design, space, ventilation, cleanliness, and sanitation during routine production [14].
1.1.1. Quality assurance
The assurance of product quality depends on
more than just proper sampling and adequate
testing of various components and the ﬁnished
dosage form. Prime responsibility of maintaining
product quality during production rests with the
manufacturing department. Quality assurance
personnel must establish control or checkpoints to
monitor the quality of the product as it is processed
and upon completion of manufacture. These begin
with raw materials and components testing and
include in process, packaging, labeling, and ﬁnished
product testing as well as batch auditing and stability monitoring [12].
1.1.2. Sources of quality variation
Because of the increasing complexity of modern
pharmaceutical manufacture arising from a variety
of unique drugs and dosage forms,complex ethical,
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legal and economic responsibilities have been
placed on those factors is the responsibility of all
those involved in the development, manufacture,
control and marketing of quality products. A systematic effective quality assurance program takes
into consideration potential raw materials,
manufacturing process, packaging material, labeling
and ﬁnished product variables [11].

2. Materials and methods
2.1. Materials
Paracetamol tablets sheets (500 mg per tablet)
from ﬁve different companies were obtained from a
local drug store in Hilla city. The randomly selected
types included Safacetol®, (SAFA Co., Private
manufacturer based in Iraq), Omol (NP Pharma Co.,
Private manufacturer based in Iraq), Paracetol (SDI
Co., Government manufacturer based in Iraq),
Apmol (AJANTA Co., Private manufacturer based in
India) and Supofen (BASI Co., Private manufacturer
based in Indiana, USA). Solvents and NaOH were
provided by Pharmaceutics Depart./College of
Pharmacy/University of Babylon.
2.2. Methods
2.2.1. Physical examination
Ten tablets where removed from the plastic blisters and carefully examined by naked eye to detect
its physical properties (appearance, color, break
line, any cracked edges or any deformations). The
process was repeatedly performed for each type of
paracetamol from different companies.
2.2.2. Weight variation test
Ten tablets where removed from the sheet of each
type separately and the weight of each tablet was
measured individually by H-digital sensitive balance (DENVER Instrument/China). The mean and
standard deviation were calculated and the accepted
values of variation of ±5% were measured and
compared with the standard deviation [11].
2.2.3. Size variation test
Ten tablets were removed from the sheet and each
tablet was placed in digital caliper (WEILIANG Co./
China) to measure its height. The steps were
repeated for the rest of the tablets and then mean
and standard deviation were calculated and
compared with the accepted ±5% value [11].

2.2.4. Friability test
Friability of tablets may be deﬁned as “the tendency
of tablet to powder, chip or fragment” and this can
affect the elegance, appearance and the consumer
acceptance of the tablet. Friability tester machine
(GUOMING CS-2/China) was used to measure friability of the different brand of paracetamol tablet [11].
The process was performed based on the guidelines of the USP as follow. The weight of 20 tablets of
each brand of paracetamol where measured and the
tablets were loaded in the friability tester. The
apparatus exposed tablets to rolling and repeated
shocks as they fall 15 cm in each turn within apparatus. After 4 min of 100 cycles, the tablets were
removed from the device, brushed to remove any
powders and weighed again. The percentage of
weight loss (Friability %) was calculated according
to the following equation:
Friability % ¼

Winitial  Wfinal
 100%
Winitial

where Winitial is the initial weight and Wf is ﬁnal
weight.
A maximum loss of weight from a single test not
greater than 1% is acceptable for most tablets based
on the USP criteria [11].
2.2.5. Disintegration test
Disintegration is a process by which tablets are
fragmented into granules or small particles. It is
deﬁned as “the time required for a group of tablets
to fragment into particles under a given set of conditions which is measured by disintegration tester”.
This test is basic for tablets intended for administration by mouth except those intended to be
chewed before being swallowed or those that should
dissolve slowly in the mouth. Moreover, disintegration test is usually does not apply to similar types
of sustained-release tablets [11].
Before each run, the apparatus (Disintegration
tester yGUOMING CS-2/China), was cleaned from
any residue of the previous test. The tank of the device
was ﬁlled with distilled water and left to reach the
desired temperature (37  C). Six tablets of paracetamol were used by putting one tablet in each basket of
the 6 tubes and ﬁxed by the speciﬁed disk. The device
was operated to start continuous immersing and
lifting of the tubes in the tank. The tablets in each tube
were carefully monitored until disintegrated
completely and the time was recorded. The mean and
standard deviation of the disintegration time were
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calculated and compared between different paracetamol brands. Values less than 10 min (600 s) were
considered as accepted values [11].
2.2.6. Hardness test
Hardness test (crushing strength) is the load
required to crushing the tablet when placed on its
edge. Hardness is the force required to break the
tablet by diametric compression tester. Usually,
tablet hardness tester is a portable semi-automatic
electronic tablet hardness tester designed to accept
tablet up to 30 mm in diameter. Unfortunately, in
this project, such device was not available within the
facility, and an alternative manual hardness tester
(Campbel HN y China) was used to perform this
test.
The hardness for ten tablets of each brand was
measured by placing 1 tablet each time in the
hardness tester and the force required to break or
crack the tablet was recorded. The mean and standard deviation of the hardness were calculated and
compared between different paracetamol brands.
Based on the USP, conventional tablet hardness
should range between 4 and 8 kg/cm2 [11]. Values
outside this range were considered unaccepted
results.
2.2.7. Content uniformity test
Uniformity of content is a pharmaceutical analysis
parameter for the quality control of capsules or
tablets. The test is performed by randomly selecting
multiple tablets and a suitable analytical method is
applied to assay the individual content of the API in
each tablet. In this project, High performance liquid
chromatography (HPLC) were chosen to perform
quantitative analysis of API in different paracetamol
tablets brands under investigation.
The HPLC analysis was performed using a shimadzu HPLC system. The column is a symmetry
C18 (250 mm  4.6 mm, 5 um particle size) maintained at 40  C and UV detection was performed at
230 nm. The mobile phase consisted of acetonitrile
and water (25:75) % at a ﬂow rate of 1 ml/min and
the injection volume was 20 uL [15].
2.2.8. Preparation of standard and reference solutions
To prepare paracetamol standard solution, 20 mg
of paracetamol reference standard (Schering, UK)
was weighed and transferred to 500 ml ﬂask. One ml
of 0.5 N NaOH was added to ensure complete solubility and the solution was diluted to 500 ml mark
with DW to give a stock solution of 40 mg ml1. A
series of dilutions were made with water to give the
concentrations of 2, 4, 8, 16, and 32 mg ml1of
paracetamol which were analyzed by HPLC to
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determine the corresponding area under the curve
(AUC) (Fig. 1).
To measure the paracetamol content in the tested
tablets, 1 tablet was ﬁnely powdered using mortar
and pestle and then transferred to 500 mL ﬂask,
0.5 N NaOH (1 ml) was added for solubility and the
solution was then diluted to mark with DW. One ml
of the resulted solution was further diluted by DW
in a ratio of 1:100. The solution was ﬁltered with 0.45
um membrane ﬁlter paper prior to analysis by
HPLC to determine the AUC. The AUCs were
converted to the corresponding concentration using
the standard curve generated by standard paracetamol solutions [15].
The percentage stated content of sample
paracetamol tablet can be calculated by using the
formula:
Percentage of stated content ¼ Calculated weight in
tablet/Expected weight in tablet  100%

3. Results and discussion
According to World Health Organization (WHO),
the term QC refers to the sum of all procedures
undertaken to ensure the identity and purity of a
particular pharmaceutical [15]. QC is an essential
operation of the pharmaceutical industry. Drugs
must be marketed as safe and therapeutically active
formulations whose performance is consistent and
predictable. It does not only protects the manufacturer against compensation claims, but also guarantees the patient a safe and effective product [16].
Thus, in addition to the apparent features of tablets, tablets must meet other physical speciﬁcations
and quality standards. These include criteria for
weight, weight variation, content uniformity, thickness, hardness, disintegration, and dissolution.
These factors must be controlled during production
(in-process controls) and veriﬁed after the production of each batch to ensure that established product
quality standards are met [14].
3.1. Physical examination
The various types of paracetamol tablet brands
were subjected to physical examination using naked
eye. The shape, engravings, color, sharpness of
edges and extent of powder loss were investigated
and the results are listed in Table 1.
3.2. Weight variation
The average weights of ten paracetamol tablets of
each brand were measured as well as the standard

42

MA'AEN JOURNAL FOR MEDICAL SCIENCES 2022;1:38e45

Fig. 1. Calibration curve of standard paracetamol powder.

deviation and the accepted values based on the
±5%. The results are listed in Table 2.
The variation in weight in tablets dosage form may
be caused by several factors such as ﬂow properties
of powders, size and shape of particles and the
amount and type of excipients [14]. The lowest weight
variation was detected in the Omol brand. The data
indicated that all types of paracetamol tablets were
within the accepted range except the Apmol brand.
3.3. Size variation
The average size of ten paracetamol tablets of
each brand were calculated as well as the standard
deviation and the accepted values based on the
±5%. The results are shown in Table 3.
Two types of paracetamol (Safacetol and Sapofen)
did not pass the size variation test while the rest of
the types were within the accepted range. The Paracetol and Apmol brands showed the best values
with minimum size variation.

The thickness of a tablet is determined by the
diameter of the die, the amount of ﬁll permitted to
enter the die, the compaction characteristics of the
ﬁll material, and the force or pressure applied during compression. Many of these factors are affected
by the ﬂow properties of powders, size and shape of
particles and the amount and type of excipients
(glidants). To produce tablets of uniform thickness
during and between batch productions for the same
formulation, care must be exercised to employ the
same factors of ﬁll, die, and pressure [14].
3.4. Friability test
Friability is the phenomenon where the surface of
the tablet is damage or shown a site of damage due
to mechanical shock. The purpose of the test is to
evaluate the ability of the tablets to withstand the
breakage during the packaging, transportation and
handling. The average percentages of weight loss of
paracetamol tablets of each brand were calculated

Table 1. Physical examination of different paracetamol brands.
Product

Description

Paracetol

Round, white tablets with excessive presence of powders and irregular edges. The tablets contain break-line with
engraved with “50000 sign.
Round, white tablets with loss of powders and irregular edges. The tablets contain a break-line with no engravings.
Round, white tablets with moderate loss of powders and irregular edges also. The tablets do not contain break-line or
any engravings.
Round, white tablets with excessive loss of powders and regular edges. The tablets contain break-line and engraved with
“50000 sign.
Round, white tablets with excessive powder loss and few tablets with irregular edges. The tablets contain a break-line
with no engravings.

Safacetol
Sapofen
Apmol
Omol
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Table 2. Weight variation of different paracetamol brands.

Table 5. Disintegration time of different paracetamol brands.

Product

Weight (mg)

SD

Acceptable value

Verdict

Paracetol
Safacetol
Sapofen
Apmol
Omol

616.07
605.73
681.64
581.41
555.93

9.19
6.31
10.72
51.98
7.11

30.80
30.28
34.08
29.07
27.79

Approved
Approved
Approved
Rejected
Approved

Product

Disintegration
time ± SD (sec)

Verdict

Paracetol
Safacetol
Sapofen
Apmol
Omol

109 ± 11
378 ± 68
161 ± 21
34 ± 5
141 ± 21

Approved
Approved
Approved
Approved
Approved

Table 3. Size variation of different paracetamol brands.
Product

Size (mm) ±SD

Paracetol
Safacetol
Sapofen
Apmol
Omol

4.303
4.369
4.273
4.273
4.137

±
±
±
±
±

0.095
0.286
0.255
0.096
0.124

Acceptable value

Verdict

0.215
0.218
0.233
0.213
0.206

Approved
Rejected
Rejected
Approved
Approved

Table 4. Percentage of weight loss of different paracetamol brands.
Product

% Wt. loss

Verdict

Paracetol
Safacetol
Sapofen
Apmol
Omol

7.71
6.53
7.29
0.2
0.24

Rejected
Rejected
Rejected
Approved
Approved

and the accepted values based on the ±5%. The
results are shown in Table 4.
The results revealed that only two brands of
paracetamol (Apmol and Omol) succeeded to pass
the test. However, other brands (Paracetol, Safacetol
and Sapofen) were out of the accepted range. The
friability is affected by the type and amount of
binder, method of preparation and the force of
compression [14].
3.5. Disintegration test
For the medicinal agent in a tablet to become
fully available for absorption, the tablet must ﬁrst
disintegrate and discharge the drug to the body
ﬂuids for dissolution. Tablet disintegration also is
important for tablets containing medicinal agents
(such as antacids and antidiarrheals) that are not
intended to be absorbed but rather to act locally
within the gastrointestinal tract. In these instances,
tablet disintegration provides drug particles with
an increased surface area for activity within the
gastrointestinal tract. All USP tablets must pass
a test for disintegration, which is conducted in
vitro using a disintegrator testing apparatus. The
average disintegration time of different paracetamol brands were determined and the results are
shown in Table 5.

The disintegration of all types of paracetamol
tablets were accepted and below the 10 min
threshold. However, the fastest time was shown by
Apmol brand (34 s). The faster disintegration time
will improve rate of dissolution rate of absorption,
bioavailability, rapid onset of action and faster
response [17]. The longest disintegration time was
related to Safacetol brand which reached almost
7 min.
3.6. Hardness test
Generally, the greater the pressure applied, the
harder the tablets, although the characteristics of the
granulation also have a bearing on hardness.
Certain tablets, such as lozenges and buccal tablets,
are intended to dissolve slowly and are intentionally
made hard; other tablets, such as those for immediate drug release, are made soft [16]. In general,
tablets should be sufﬁciently hard to resist breaking
during normal handling and yet soft enough to
disintegrate properly after swallowing. A force of
about 4 kg is considered the minimum requirement
for a satisfactory tablet [11]. Multifunctional automated equipment can determine weight, hardness,
thickness, and diameter of the tablet. The average
hardness of different paracetamol brands were
determined and the results are shown in Table 6.
3.7. Contents uniformity test
To ensure the consistency of dosage units, each
unit in a batch should have a drug substance content within a narrow range around the label claim.
The term “uniformity of dosage unit” is deﬁned as
the degree of uniformity in the amount of the drug
Table 6. Hardness of different paracetamol brands.
Product

Hardness ± SD (Kg)

Verdict

Paracetol
Safacetol
Sapofen
Apmol
Omol

109 ± 11
378 ± 68
161 ± 21
34 ± 5
141 ± 21

Approved
Approved
Approved
Approved
Approved
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Table 7. Average API contents & percentages of stated contents of
different paracetamol brands.
Product

Average API
content ±
SD (mg)

Paracetol
Safacetol
Sapofen
Apmol
Omol

539
528
533
504
525

±
±
±
±
±

28
44
37
10
16

Percentage
of stated
content

Verdict

107.8%
105.6%
106.6%
100.8%
105%

Approved
Approved
Approved
Approved
Approved

substance among dosage units. The test for Content
Uniformity of preparations presented in dosage
units is based on the quantitative assay of the individual content of drug substance(s) in a number of
dosage units to determine whether the individual
content is within the limits set. The Content Uniformity method may be applied in all cases [11].
To perform this test, tablets from each brands
were subjected to quantitative analysis of the API
using HPLC. The API produced a distinctive peak in
monograph which eluted at minute 6 of the run
time.
The AUCs for each run were recorded and the
corresponding percentage of contents were calculated for each brand which are listed in Table 7.
The results indicated that all tablet brands under
investigation contained higher contents of the API
(paracetamol) than the stated content (500 mg). This
may be attributed to the fact that the raw material of
the API is commercially cheap in addition to the
wide therapeutic window of the drug (minimum
chance of drug toxicity in even in higher concentrations). For such reasons many manufacturer may
turn a blind eye for such higher API contents.
In general, it is essential for drug manufacturers to
maintain the quality of their products by performing
various QC testing to make sure that it is safe and at
the same time, it maintains the efﬁciency and quality
of the overall product. QC testing also makes sure that
the drug adheres to the details as per the description
and data listed on the drug label. This may include
checking the purities and impurities in a drug, API
content, drug absorption by the body, etc. The in vitro
testing performed in these tests determines the
quality, efﬁcacy, and effectiveness of paracetamol
drug as required by the standards of the USP.

4. Conclusion
Different brands of paracetamol tablets which are
widely available in Iraqi market were subjected to
different QC test to indicate whether it will meet the
criteria of USP for tablets manufacturing. It should be
kept in mind that, the aim of this study was not to

favour a certain brand or company on the others, nor
to prove that a certain manufacturer or the more
expensive product is better than other manufacturers
or the lower cost product. Such comparative studies
are usually performed by drug companies as a part
of their marketing and advertising propaganda to
try to demonstrate to health care professional and
consumers that their products is better than other
drug providers. Such claims should not be taken
for granted by scientiﬁc researchers and instead researchers must be unbiased and not affected by such
propaganda. Ofﬁcial QC tests may be applied to
prove whether these claims are right or wrong.
In conclusion, the ﬁve different brands of the
tested drug showed variable results, which is quite
expected not only for different manufacturers but
also for different batches of the same company.
Only the brand type, Omol, passed all tests included
in this study based on the QC standards of the USP.
The four other brands did not pass all tests and
based on the USP such batches may not be
approved. However, it should be kept in mind, that
these results may be affected by many factors such
as shipment method, storage conditions and production date and such factors were not taken in
consideration in this study.
Finally, this research can be expanded to be used
to prove or refute manufacturers claims not only for
paracetamol, but for other active pharmaceutical
ingredients.

Conﬂicts of interest
The authors certify that there is no conﬂict of
interest.

Funding
None to declare.

References
[1] Towheed T, Maxwell L, Judd M, Catton M, Hochberg MC,
Wells GA. Acetaminophen for osteoarthritis. Cochrane
Database Syst Rev 2006;(1). https://doi.org/10.1002/
14651858.CD004257.pub2.
[2] McKay GA, Reid JL, Walters MR. Lecture notes: clinical
pharmacology and therapeutics. John Wiley & Sons; 2010.
[3] Milani DAQ, Davis DD. Pain management medications.
StatPearls Publishing; 2022. StatPearls [Internet].
[4] Bannwarth B, Pehourcq F. Pharmacological rationale for the
clinical use of paracetamol: pharmacokinetic and pharmacodynamic issues. Drugs 2003;63:5e13. PMID: 14758786.
[5] Smith HS. Potential analgesic mechanisms of acetaminophen. Pain Physician 2009;12(1):269e80. PMID: 19165309.
[6] Marmura MJ, Silberstein SD, Schwedt TJ. The acute treatment of migraine in adults: the a merican H eadache S ociety
evidence assessment of migraine pharmacotherapies.
Headache J Head Face Pain 2015;55(1):3e20. https://doi.org/
10.1111/head.12499.

MA'AEN JOURNAL FOR MEDICAL SCIENCES 2022;1:38e45

[7] Kulo A, Peeters MY, Allegaert K, Smits A, de Hoon J,
Verbesselt R, et al. Pharmacokinetics of paracetamol and its
metabolites in women at delivery and post-partum. Br J Clin
Pharmacol 2013;75(3):850e60. https://doi.org/10.1111/j.13652125.2012.04402.x.
[8] Wang X, Wu Q, Liu A, Anad
on A, Rodríguez J-L, MartínezLarra~
naga M-R, et al. Paracetamol: overdose-induced oxidative stress toxicity, metabolism, and protective effects of
various compounds in vivo and in vitro. Drug Metab Rev 2017;
49(4):395e437. https://doi.org/10.1080/03602532.2017.1354014.
[9] Williams CM, Maher CG, Latimer J, McLachlan AJ,
Hancock MJ, Day RO, et al. Efﬁcacy of paracetamol for acute
low-back pain: a double-blind, randomised controlled trial.
Lancet
2014;384(9954):1586e96.
https://doi.org/10.1016/
S0140-6736(14)60805-9. Epub 2014 Jul 23.
[10] Su S-F, Chou C-H, Kung C-F, Huang J-d. In vitro and in vivo
comparison of two diclofenac sodium sustained release oral
formulations. Int J Pharm 2003;260(1):39e46. https://doi.org/
10.1016/s0378-5173(03)00237-0.
[11] Pharmacopeia US. USP 37eNF 32. USP-NF Standard Updates 2013;37 (second supplement).

45

[12] Allen L, Ansel HC. Ansel's pharmaceutical dosage forms and
drug delivery systems. Lippincott Williams & Wilkins; 2013.
[13] Gupta MM, Gupta M. In-vitro pharmaceutical quality control testing: a comparative study of different brands of metformin tablets available in the Trinidad & Tobago, West
Indies. J Pharmaceut Sci Res 2016;8(4):238.
[14] Lachman L, Lieberman H, Khar R, Vyas S, Farhan A, Jain J.
The theory and practice of industrial pharmacy. 4th ed., vol.
245. New Delhi: CBS Publishers & Distributors Pvt Ltd; 2013.
p. 450e8.
[15] Franeta J, Agbaba D, Eric S, Pavkov S, Aleksic M,
Vladimirov S. HPLC assay of acetylsalicylic acid, paracetamol,
caffeine and phenobarbital in tablets. Il Farmaco 2002;57(9):
709e13. https://doi.org/10.1016/s0014-827x(02)01265-x.
[16] Organisation WH. Supplementary guidelines on good
manufacturing practices: validation. (2006). Appendix 4 on
Analytical method validationvol. 937. WHO Tech Rep Ser;
2006 (Annex 4).
[17] Shargel L, Wu-Pong S. Andrew yu applied biopharmaceutics and pharmacokinetics. McGraw-Hill Education; 2015.

